Login / Signup

Dabrafenib plus Trametinib: A breakthrough in pediatric low-grade glioma therapy.

Marrium Sultan DarNayab ShahidArisha WaqasYumna Arif BaigAimen Waqar Khan
Published in: Health science reports (2024)
The introduction of D+T as a targeted therapy represents a significant advancement in the management of pLGG, necessitating further investigations to understand its long-term consequences and optimize patient care.
Keyphrases
  • low grade
  • high grade
  • stem cells
  • young adults
  • cell therapy
  • childhood cancer